William G. Kaelin

68.2k citations

246 papers · 50.2k indexed · 55 hit papers · h-index 117

Molecular Biology top 0.02%
Cancer Research top 0.01%
Oncology top 0.05%
Pulmonary and Respiratory Medicine top 0.1%
Genetics top 0.1%

Co-authors: Peter J. Ratcliffe Mircea Ivan Keiichi Kondo Michael Ohh Othon Iliopoulos David M. Livingston Haifeng Yang William Y. Kim
Topics: Cancer, Hypoxia, and Metabolism (124 papers)Cancer-related Molecular Pathways (72 papers)Epigenetics and DNA Methylation (47 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Nature Science Cell
Partner nations: United States United Kingdom Canada

In The Last Decade

William G. Kaelin

243 papers receiving 49.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O ₂ Sensing

2001 3.9k citations Michael Ohh, William G. Kaelin et al. Science profile →
Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway

2008 2.5k citations William G. Kaelin, Peter J. Ratcliffe profile →
Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

2000 1.3k citations Michael Ohh, Nikola P. Pavletich et al. profile →
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

2013 1.1k citations Gang Lu, Richard E. Middleton et al. Science profile →
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

2004 1.1k citations William G. Kaelin et al. profile →
The Concept of Synthetic Lethality in the Context of Anticancer Therapy

2005 1.0k citations William G. Kaelin profile →
p73 is a human p53-related protein that can induce apoptosis

1997 835 citations William G. Kaelin et al. profile →
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

1999 785 citations William G. Kaelin et al. profile →
Expression cloning of a cDNA encoding a retinoblastoma-binding protein with E2F-like properties

1992 777 citations William G. Kaelin, William R. Sellers et al. profile →
Role ofVHLGene Mutation in Human Cancer

2004 727 citations William Y. Kim, William G. Kaelin profile →
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.

1996 713 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function

1999 689 citations C. Erec Stebbins, William G. Kaelin et al. Science profile →
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation

1996 661 citations William G. Kaelin et al. profile →
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase

1999 661 citations William G. Kaelin, Ronald Conaway et al. Science profile →
Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis.

1994 658 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
Influence of Metabolism on Epigenetics and Disease

2013 654 citations William G. Kaelin et al. profile →
Molecular basis of the VHL hereditary cancer syndrome

2002 637 citations William G. Kaelin profile →
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

2002 635 citations Eijiro Nakamura, William G. Kaelin et al. Cancer Cell profile →
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling

2002 619 citations William G. Kaelin, Nikola P. Pavletich et al. Science profile →
Role for the p53 homologue p73 in E2F-1-induced apoptosis

2000 592 citations William G. Kaelin et al. profile →
Tumour suppression by the human von Hippel-Lindau gene product

1995 577 citations William G. Kaelin et al. Nature Medicine profile →
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation

2012 566 citations Peppi Koivunen, Sung-Woo Lee et al. profile →
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer

2008 549 citations William G. Kaelin profile →
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C

1995 539 citations William G. Kaelin et al. Science profile →
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

2013 533 citations Ryan Looper, Peppi Koivunen et al. Science profile →
The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families

1998 507 citations William G. Kaelin, Ronald Conaway et al. profile →
Identification of cellular proteins that can interact specifically with the T/ElA-binding region of the retinoblastoma gene product

1991 496 citations William G. Kaelin et al. profile →
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth

2003 481 citations William Y. Kim, William G. Kaelin et al. profile →
Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor

2002 478 citations Volkmar Günzler, Ronald Conaway et al. Proceedings of the National Academy of Sciences profile →
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

2000 442 citations William G. Kaelin et al. profile →
Suppression of tumor growth through disruption of hypoxia-inducible transcription

2000 436 citations Jeffery M. Klco, William G. Kaelin et al. Nature Medicine profile →
TSC2 regulates VEGF through mTOR-dependent and -independent pathways

2003 429 citations William R. Sellers, William G. Kaelin et al. Cancer Cell profile →
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer

2013 424 citations William G. Kaelin et al. profile →
Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: Developmental culling and cancer

2005 417 citations Sung-Woo Lee, Eijiro Nakamura et al. Cancer Cell profile →
Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex

2001 410 citations Qin Yan, William G. Kaelin et al. profile →
Degradation of the SCF component Skp2 in cell-cycle phase G1 by the anaphase-promoting complex

2004 400 citations William G. Kaelin et al. profile →
von Hippel-Lindau Disease

1997 395 citations William G. Kaelin et al. profile →
The von Hippel-Lindau Tumor Suppressor Protein Is Required for Proper Assembly of an Extracellular Fibronectin Matrix

1998 395 citations Michael Ohh, William G. Kaelin et al. profile →
PROLINE HYDROXYLATION AND GENE EXPRESSION

2005 389 citations William G. Kaelin profile →
Identification of a growth suppression domain within the retinoblastoma gene product.

1992 379 citations William G. Kaelin et al. profile →
The T/E1A-binding domain of the retinoblastoma product can interact selectively with a sequence-specific DNA-binding protein

1991 364 citations William G. Kaelin et al. profile →
Chemosensitivity linked to p73 function

2003 345 citations William G. Kaelin et al. Cancer Cell profile →
The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase

2005 337 citations Susanne Schlisio, William G. Kaelin et al. Cancer Cell profile →
The Retinoblastoma Binding Protein RBP2 Is an H3K4 Demethylase

2007 336 citations Qin Yan, William G. Kaelin et al. profile →
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

2016 336 citations Abhishek A. Chakraborty, Sabina Signoretti et al. profile →
Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors

1996 323 citations William R. Sellers, William G. Kaelin et al. Molecular and Cellular Biology profile →
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene

2011 313 citations Chuan Shen, Rameen Beroukhim et al. Cancer Discovery profile →
Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney

2009 310 citations Rameen Beroukhim, Arianna Di Napoli et al. Cancer Research profile →
Targeting the HIF2–VEGF axis in renal cell carcinoma

2020 299 citations Toni K. Choueiri, William G. Kaelin Nature Medicine profile →
The VHL/HIF axis in clear cell renal carcinoma

2012 294 citations Chuan Shen, William G. Kaelin profile →
E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product.

1993 286 citations William G. Kaelin et al. Proceedings of the National Academy of Sciences profile →
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate

2019 280 citations Abhishek A. Chakraborty, Matti Myllykoski et al. Science profile →
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes

2015 248 citations William G. Kaelin, Peppi Koivunen et al. profile →
The EGLN-HIF O 2 -Sensing System: Multiple Inputs and Feedbacks

2017 198 citations William G. Kaelin et al. profile →
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine

2016 193 citations Peppi Koivunen, Benjamin A. Olenchock et al. profile →

Peers

Countries citing papers authored by William G. Kaelin

Since Specialization

Citations

This map shows the geographic impact of William G. Kaelin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William G. Kaelin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William G. Kaelin more than expected).

Fields of papers citing papers by William G. Kaelin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William G. Kaelin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William G. Kaelin. The network helps show where William G. Kaelin may publish in the future.

Co-authorship network of co-authors of William G. Kaelin

This figure shows the co-authorship network connecting the top 25 collaborators of William G. Kaelin. A scholar is included among the top collaborators of William G. Kaelin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William G. Kaelin. William G. Kaelin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting of HIF2-driven cachexia in kidney cancer 2025 ·Nature Medicine ·Muhannad Abu‐Remaileh,Laura Stransky,(unknown),Nitin H. Shirole,Qinqin Jiang,Eddy Saad,(unknown),(unknown),(unknown),Chunbao Xu,Jing Lu,Hairong Wei,Zhihong Liu,William Sun,Kei Enomoto,Toni K. Choueiri,Jason R. Pitarresi,Steven A. Carr,Namrata D. Udeshi,William G. Kaelin	0
2	Induction of DEPP1 by HIF Mediates Multiple Hallmarks of Ischemic Cardiomyopathy 2024 ·Circulation ·Gregory A. Wyant,Qinqin Jiang,(unknown),Shariq Qayyum,(unknown),Bradley A. Maron,William G. Kaelin	6
3	Mitochondrial remodeling and ischemic protection by G protein–coupled receptor 35 agonists 2022 ·Science ·Gregory A. Wyant,Wenyu Yu,(unknown),(unknown),Mossab Y. Saeed,Thomas Duignan,James D. McCully,William G. Kaelin	70
4	Sensitivity ofVHLmutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway 2022 ·Proceedings of the National Academy of Sciences ·Laura Stransky,(unknown),(unknown),(unknown),Thomas Denize,Emily Walton,Sabina Signoretti,William G. Kaelin	21
5	Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma 2019 ·JCI Insight ·Nilay S. Sethi,Osamu Kikuchi,James M. McFarland,Yanxi Zhang,Shen Shou Max Chung,(unknown),Mirazul Islam,Benjamin L. Lampson,Abhishek A. Chakraborty,William G. Kaelin,Adam J. Bass	22
6	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fatebreakdown → 2019 ·Science ·Abhishek A. Chakraborty,(unknown),Matti Myllykoski,Alison E. Ringel,Matthew A. Booker,Michael Tolstorukov,Yuzhong Jeff Meng,Samuel R. Meier,Rebecca B. Jennings,Amanda L. Creech,Zachary T. Herbert,Samuel K. McBrayer,Benjamin A. Olenchock,Jacob D. Jaffe,Marcia C. Haigis,Rameen Beroukhim,Sabina Signoretti,Peppi Koivunen,William G. Kaelin	280
7	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase 2017 ·Science Translational Medicine ·Abhishek A. Chakraborty,Eijiro Nakamura,Jun Qi,Amanda L. Creech,Jacob D. Jaffe,Joshiawa Paulk,Jesse Novak,Kshithija Nagulapalli,Samuel K. McBrayer,Glenn S. Cowley,Javier Pineda,Jiaxi Song,Yaoyu E. Wang,Steven A. Carr,David E. Root,Sabina Signoretti,James E. Bradner,William G. Kaelin	36
8	EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection 2016 ·DSpace@MIT (Massachusetts Institute of Technology) ·Benjamin A. Olenchock,Javid J. Moslehi,Alan H. Baik,(unknown),William J. Gibson,Abhishek A. Chakraborty,Kerry A. Pierce,Christine Miller,Eric A. Hanse,Ameeta Kelekar,Amy J. Wagers,Clary B. Clish,William G. Kaelin,Shawn M. Davidson,(unknown),Matthew G. Vander Heiden	1
9	Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate 2015 ·Clinical Cancer Research ·Ovidiu C. Andronesi,Franziska Loebel,Wolfgang Bogner,Małgorzata Marjańska,Matthew G. Vander Heiden,A. John Iafrate,Jörg Dietrich,Tracy T. Batchelor,Elizabeth R. Gerstner,William G. Kaelin,S. Andrew,Bruce R. Rosen,Daniel P. Cahill	116
10	( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversiblebreakdown → 2013 ·Science ·(unknown),Ryan Looper,Peppi Koivunen,Sung-Woo Lee,Rebekka K. Schneider,Christine M. McMahon,Glenn S. Cowley,David E. Root,Benjamin L. Ebert,William G. Kaelin	533
11	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteinsbreakdown → 2013 ·Science ·Gang Lu,Richard E. Middleton,Huahang Sun,(unknown),Christopher J. Ott,Constantine S. Mitsiades,Kwok‐Kin Wong,James E. Bradner,William G. Kaelin	1108
12	Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Genebreakdown → 2011 ·Cancer Discovery ·Chuan Shen,Rameen Beroukhim,Steven E. Schumacher,Jing Zhou,Michelle Chang,Sabina Signoretti,William G. Kaelin	313
13	Mutation analysis of HIF prolyl hydroxylases (PHD/EGLN) in individuals with features of phaeochromocytoma and renal cell carcinoma susceptibility 2010 ·Endocrine Related Cancer ·Dewi Astuti,Christopher J. Ricketts,Rasheduzzaman Chowdhury,M.A. McDonough,Dean Gentle,Gail Kirby,Susanne Schlisio,Rajappa S. Kenchappa,(unknown),William G. Kaelin,Peter J. Ratcliffe,Christopher J. Schofield,Farida Latif,Eamonn R. Maher	48
14	FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis 2010 ·Cancer Cell ·Boyi Gan,Carol S. Lim,Gerald Chu,Sujun Hua,Zhihu Ding,Michael P. Collins,Jian Hu,Shan Jiang,Eliot Fletcher-Sananikone,Li Zhuang,Michelle Chang,Hongwu Zheng,Yanru Wang,David J. Kwiatkowski,William G. Kaelin,Sabina Signoretti,Ronald A. DePinho	116
15	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidneybreakdown → 2009 ·Cancer Research ·Rameen Beroukhim,(unknown),Arianna Di Napoli,Kirsten D. Mertz,Apryle Seeley,Maira M. Pires,David Linhart,Robert Worrell,Holger Moch,Mark A. Rubin,William R. Sellers,Matthew Meyerson,W. Marston Linehan,William G. Kaelin,Sabina Signoretti	310
16	The Hypoxia-Inducible Factor 2α N-Terminal and C-Terminal Transactivation Domains Cooperate To Promote Renal Tumorigenesis In Vivo 2007 ·Molecular and Cellular Biology ·Qin Yan,Steven R. Bartz,Mao Mao,Lianjie Li,William G. Kaelin	154
17	Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: Assessment of an oral agent that stimulates erythropoietin production 2005 ·Proceedings of the National Academy of Sciences ·Michal Safran,William Y. Kim,Fionnuala O’Connell,Lee A. Flippin,Volkmar Günzler,James W. Horner,Ronald A. DePinho,William G. Kaelin	238
18	Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist 2004 ·Proceedings of the National Academy of Sciences ·Bogdan Olenyuk,Guo‐Jun Zhang,Jeffery M. Klco,Nicholas G. Nickols,William G. Kaelin,Peter B. Dervan	181
19	Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein 1999 ·Journal of Clinical Investigation ·Michael Ohh,Yuichiro Takagi,Teijiro Aso,C. Erec Stebbins,Nikola P. Pavletich,Bert Zbar,Ronald Conaway,Joan Conaway,William G. Kaelin	86
20	Recent Insights into the Functions of the Retinoblastoma Susceptibility Gene Product 1997 ·Cancer Investigation ·William G. Kaelin	32

About William G. Kaelin

William G. Kaelin is a scholar working on Cancer Research, Oncology and Biotechnology, having authored 246 papers that have together received 50.2k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (124 papers), Cancer-related Molecular Pathways (72 papers) and Epigenetics and DNA Methylation (47 papers). The work is most often cited by research in Cancer Research (22.6k citations), Oncology (14.8k citations) and Molecular Biology (35.6k citations). William G. Kaelin has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Peter J. Ratcliffe, Mircea Ivan, Keiichi Kondo, Michael Ohh, Othon Iliopoulos, David M. Livingston, Haifeng Yang, William Y. Kim, William R. Sellers and Nikola P. Pavletich. Their work appears in journals such as Nature, Science and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact